M. S. Demin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
M. S. Demin has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- O. N. Anoshenkova
Tomsk Regional Clinical Hospital
2 shared publications - Olga I. Urazova
Siberian State Medical University
2 shared publications - Sergey L. Andreev
Cardiology Research Institute, Tomsk National Research Medical Center (Cardiology Research Institute, Tomsk NRMC), Russian Academy of Sciences
2 shared publications - Svetlana P. Chumakova
Siberian State Medical University; Immanuel Kant Baltic Federal University
2 shared publications - Vladimir M. Shipulin
Tomsk National Research Medical Center, Cardiology Research Institute
2 shared publications A. G. Gulomzhonov
Immanuel Kant Baltic Federal University
1 shared publication
Latest Publications
- Open Access
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 113-118
Coexistence of psoriatic arthritis and systemic lupus erythematosus in rheumatology practice: challenges of patient management and treatment selection (literature review and clinical case)
We present a clinical case of the coexistence of two autoimmune diseases, psoriatic arthritis and systemic lupus erythematosus. Diagnostic challenges are analyzed, as manifestations of one disease may mask the activity of the other, leading to delays in initiating appropriate therapy. Particular attention is paid to treatment selection, considering the mutual influence of the diseases and the risk of adverse reactions. A risk-minimization strategy is discussed, ranging from careful monitoring to the successful selection of a biologic agent based on its safety profile. This observation highlights the need for an individualized patient management strategy and a multidisciplinary approach.
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 113-118
Open AccessCoexistence of psoriatic arthritis and systemic lupus erythematosus in rheumatology practice: challenges of patient management and treatment selection (literature review and clinical case)
We present a clinical case of the coexistence of two autoimmune diseases, psoriatic arthritis and systemic lupus erythematosus. Diagnostic challenges are analyzed, as manifestations of one disease may mask the activity of the other, leading to delays in initiating appropriate therapy. Particular attention is paid to treatment selection, considering the mutual influence of the diseases and the risk of adverse reactions. A risk-minimization strategy is discussed, ranging from careful monitoring to the successful selection of a biologic agent based on its safety profile. This observation highlights the need for an individualized patient management strategy and a multidisciplinary approach.
- Open Access
- 22 April 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (2) , 82-86
Use of olokizumab in giant cell arteritis with rapidly progressive ischemic optic neuropathy (clinical case)
We present a clinical case of giant cell arteritis (GCA) with ophthalmic manifestations (anterior ischemic optic neuropathy) successfully treated with the direct interleukin-6 inhibitor olokizumab in combination with glucocorticoids. This case demonstrates the efficacy of early initiation of biologic drugs for rapid control of inflammatory activity and prevention of irreversible vision loss in GCA.
- 22 April 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (2) , 82-86
Open AccessUse of olokizumab in giant cell arteritis with rapidly progressive ischemic optic neuropathy (clinical case)
We present a clinical case of giant cell arteritis (GCA) with ophthalmic manifestations (anterior ischemic optic neuropathy) successfully treated with the direct interleukin-6 inhibitor olokizumab in combination with glucocorticoids. This case demonstrates the efficacy of early initiation of biologic drugs for rapid control of inflammatory activity and prevention of irreversible vision loss in GCA.
- 30 January 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (11)
Ischemic cardiomyopathy is characterized by insufficient proinflammatory and proangiogenic myocardial response associated with a blood HIF‑1/2 imbalance
Aim . To identify the role of impaired production of hypoxia-inducible factors (HIF) 1 and 2 in determining the balance of angiogenesis mediators, pro- and antiinflammatory cytokines in peripheral and coronary sinus blood in patients with coronary artery disease (CAD), with and without ischemic cardiomyopathy (ICM). Material and methods . The study included 30 patients with coronary artery disease (CAD) and non-cardiomyopathy, 22 patients with CAD without cardiomyopathy, and 20 healthy donors. Patients with non-cardiomyopathy had a lower left ventricular ejection fraction (LVEF) compared to CAD patients without cardiomyopathy (30,00 [22,00; 36,00]% and 59,50 [50,25; 67,00]%, pResults . In the peripheral blood of patients with CAD, regardless of ICM, the concentration of TNF-α, IL-6, VEGF-A, PDGF was normal, while the SCF level showed a tendency to increase (p=0,054), and TGF-β1 — to decrease (p=0,059); excess IL-10 and HIF-2α was determined only in patients with ICM (respectively, 2,80 [2,00; 3,30] pg/ml versus 1,78 [0,50; 2,40] pg/ml, p=0,018; 40,0% vs 0% of positive cases, p=0,047), excess HIF-1α — only in CAD patients without cardiomyopathy (6,00 [5,00; 6,20] ng/ml and 4,60 [3,28; 5,11] ng/ml, p=0,049). In the coronary flow relative to the peripheral flow in CAD patients without ICM, the concentration of TNF-α, IL-6, PDGF was higher (1,09 [0,68; 2,47] pg/ml, p=0,004; 5,85 [3,12; 7,15] pg/ml, p=0,011; 7,60 [3,70; 9,94] pg/ml, p=0,036), which was not determined in patients with ICM, who had a higher content of TGF-β1 (4,42 [3,38; 5,69] pg/ml, p=0,022). Regardless of ICM type, the VEGF-A content in sinus blood exceeded the systemic level (7,80 [3,25; 9,75] pg/ml, p=0,041), while the concentration of HIF-1α, IL-10, and SCF corresponded to them. Conclusion . Insufficient cardiac angiogenesis in ICM is largely associated with the anergy of the myocardial proinflammatory response with atherogenesis, rather than with reduced response to hypoxia. This, on the contrary, is more significant at the systemic level in ICM pathogenesis and is characterized by the predominance of HIF-2 over HIF-1.
- 30 January 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (11)
Ischemic cardiomyopathy is characterized by insufficient proinflammatory and proangiogenic myocardial response associated with a blood HIF‑1/2 imbalance
Aim . To identify the role of impaired production of hypoxia-inducible factors (HIF) 1 and 2 in determining the balance of angiogenesis mediators, pro- and antiinflammatory cytokines in peripheral and coronary sinus blood in patients with coronary artery disease (CAD), with and without ischemic cardiomyopathy (ICM). Material and methods . The study included 30 patients with coronary artery disease (CAD) and non-cardiomyopathy, 22 patients with CAD without cardiomyopathy, and 20 healthy donors. Patients with non-cardiomyopathy had a lower left ventricular ejection fraction (LVEF) compared to CAD patients without cardiomyopathy (30,00 [22,00; 36,00]% and 59,50 [50,25; 67,00]%, pResults . In the peripheral blood of patients with CAD, regardless of ICM, the concentration of TNF-α, IL-6, VEGF-A, PDGF was normal, while the SCF level showed a tendency to increase (p=0,054), and TGF-β1 — to decrease (p=0,059); excess IL-10 and HIF-2α was determined only in patients with ICM (respectively, 2,80 [2,00; 3,30] pg/ml versus 1,78 [0,50; 2,40] pg/ml, p=0,018; 40,0% vs 0% of positive cases, p=0,047), excess HIF-1α — only in CAD patients without cardiomyopathy (6,00 [5,00; 6,20] ng/ml and 4,60 [3,28; 5,11] ng/ml, p=0,049). In the coronary flow relative to the peripheral flow in CAD patients without ICM, the concentration of TNF-α, IL-6, PDGF was higher (1,09 [0,68; 2,47] pg/ml, p=0,004; 5,85 [3,12; 7,15] pg/ml, p=0,011; 7,60 [3,70; 9,94] pg/ml, p=0,036), which was not determined in patients with ICM, who had a higher content of TGF-β1 (4,42 [3,38; 5,69] pg/ml, p=0,022). Regardless of ICM type, the VEGF-A content in sinus blood exceeded the systemic level (7,80 [3,25; 9,75] pg/ml, p=0,041), while the concentration of HIF-1α, IL-10, and SCF corresponded to them. Conclusion . Insufficient cardiac angiogenesis in ICM is largely associated with the anergy of the myocardial proinflammatory response with atherogenesis, rather than with reduced response to hypoxia. This, on the contrary, is more significant at the systemic level in ICM pathogenesis and is characterized by the predominance of HIF-2 over HIF-1.
- Open Access
- 14 January 2024
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 8 (6) , 81-90
Production of angiogenesis mediators and the structure of the vascular wall in the heart in ischemic cardiomyopathy
Background. In the pathogenesis of ischemic cardiomyopathy (ICMP), angiopoiesis remains unexplored.The aim. To describe the vasculature of the heart and the imbalance of angiogenesis mediators in the coronary circulation in association with the number of endothelial progenitor cells (EPC) and desquamated endothelial cells (DEC) in the blood of patients with coronary heart disease (CHD), suffering and not suffering from ICMP.Methods. Fifty-two patients with CHD (30 patients with ICMP, 22 patients without ICMP), 15 healthy donors were examined. The content of EPC (CD14+CD34+VEGFR2+) in the blood from the cubital vein and DEC (CD45–CD146+) in the blood from the coronary sinus and the cubital vein was determined by flow cytometry. The concentrations of VEGF-A (vascular endothelial growth factor A), PDGF (platelet-derived growth factor), and SDF-1 (stromal cell-derived factor 1) in blood plasma were recorded using immunofluorescence assay; the angiopoietin-2, MMP-9 (matrix metallopeptidase 9) were recorded using enzyme immunoassay. In myocardial biopsies the specific area of vessels and the expression of αSMA (smooth muscle alpha-actin) were determined by morphometric and immunohistochemical methods.Results. In the peripheral blood of patients with CHD, regardless of the presence of ICMP, the DEC content exceeded the physiological level, and the VEGF-A, PDGF, angiopoietin-2, and MMP-9 corresponded to the norm. In CHD patients without cardiomyopathy, there was an excess of SDF-1 and EPC in the blood from the cubital vein, and in ICMP, their physiological significance was noted. In the coronary blood flow in patients with CHD without cardiomyopathy, an increase in the concentration of PDGF was found, which was not determined in patients with ICMP, who had an increased content of DEC, angiopoietin-2 and MMP-9. The specific area of the vessels in the patients of the two groups was comparable; the expression of αSMA in ICMP was 6.2 times lower than in patients with CHD without cardiomyopathy.Conclusion. The development of ICMP is accompanied by impaired maturation of vessels in the myocardium, associated with the absence of a compensatory reaction of activation of cellular and humoral factors of angiogenesis.
- 14 January 2024
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 8 (6) , 81-90
Open AccessProduction of angiogenesis mediators and the structure of the vascular wall in the heart in ischemic cardiomyopathy
Background. In the pathogenesis of ischemic cardiomyopathy (ICMP), angiopoiesis remains unexplored.The aim. To describe the vasculature of the heart and the imbalance of angiogenesis mediators in the coronary circulation in association with the number of endothelial progenitor cells (EPC) and desquamated endothelial cells (DEC) in the blood of patients with coronary heart disease (CHD), suffering and not suffering from ICMP.Methods. Fifty-two patients with CHD (30 patients with ICMP, 22 patients without ICMP), 15 healthy donors were examined. The content of EPC (CD14+CD34+VEGFR2+) in the blood from the cubital vein and DEC (CD45–CD146+) in the blood from the coronary sinus and the cubital vein was determined by flow cytometry. The concentrations of VEGF-A (vascular endothelial growth factor A), PDGF (platelet-derived growth factor), and SDF-1 (stromal cell-derived factor 1) in blood plasma were recorded using immunofluorescence assay; the angiopoietin-2, MMP-9 (matrix metallopeptidase 9) were recorded using enzyme immunoassay. In myocardial biopsies the specific area of vessels and the expression of αSMA (smooth muscle alpha-actin) were determined by morphometric and immunohistochemical methods.Results. In the peripheral blood of patients with CHD, regardless of the presence of ICMP, the DEC content exceeded the physiological level, and the VEGF-A, PDGF, angiopoietin-2, and MMP-9 corresponded to the norm. In CHD patients without cardiomyopathy, there was an excess of SDF-1 and EPC in the blood from the cubital vein, and in ICMP, their physiological significance was noted. In the coronary blood flow in patients with CHD without cardiomyopathy, an increase in the concentration of PDGF was found, which was not determined in patients with ICMP, who had an increased content of DEC, angiopoietin-2 and MMP-9. The specific area of the vessels in the patients of the two groups was comparable; the expression of αSMA in ICMP was 6.2 times lower than in patients with CHD without cardiomyopathy.Conclusion. The development of ICMP is accompanied by impaired maturation of vessels in the myocardium, associated with the absence of a compensatory reaction of activation of cellular and humoral factors of angiogenesis.